Tumor Necrosis Factor Ligand Superfamily Member 13
"Tumor Necrosis Factor Ligand Superfamily Member 13" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of tumor necrosis factor superfamily found on MACROPHAGES; DENDRITIC CELLS and T-LYMPHOCYTES. It occurs as transmembrane protein that can be cleaved to release a secreted form that specifically binds to TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; and B CELL MATURATION ANTIGEN.
| Descriptor ID |
D053300
|
| MeSH Number(s) |
D12.644.276.374.750.656 D12.776.467.374.750.656 D23.529.374.750.656
|
| Concept/Terms |
Tumor Necrosis Factor Ligand Superfamily Member 13- Tumor Necrosis Factor Ligand Superfamily Member 13
- TNF- and APOL-Related Leukocyte Expressed Ligand 2 Protein
- TNF and APOL Related Leukocyte Expressed Ligand 2 Protein
- TALL-2 Protein
- TALL 2 Protein
- A Proliferation Inducing Ligand Protein
- APRIL Protein
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor Ligand Superfamily Member 13".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor Ligand Superfamily Member 13".
This graph shows the total number of publications written about "Tumor Necrosis Factor Ligand Superfamily Member 13" by people in this website by year, and whether "Tumor Necrosis Factor Ligand Superfamily Member 13" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Necrosis Factor Ligand Superfamily Member 13" by people in Profiles.
-
CNS Autoimmune Responses in BCMA-Deficient Mice Provide Insight for the Failure of Atacicept in MS. Neurol Neuroimmunol Neuroinflamm. 2021 05; 8(3).
-
Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders. Front Immunol. 2020; 11:592639.
-
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheumatol. 2018 02; 70(2):266-276.
-
BAFF- and APRIL-dependent maintenance of antibody titers after immunization with T-dependent antigen and CD1d-binding ligand. J Immunol. 2013 Aug 01; 191(3):1154-63.
-
APRIL polymorphism and systemic lupus erythematosus (SLE) susceptibility. Rheumatology (Oxford). 2007 Aug; 46(8):1274-6.